Legal regulation of gene editing procedure: USA and EU experience
The problem of legal regulation of gene editing in recent years has obviously become global in nature due to the lack of unified systematic legislation in the world. The authors set a goal to study the main existing regulatory legal acts and determine whether there is currently an array of legislati...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Peoples’ Friendship University of Russia (RUDN University)
2021-12-01
|
Series: | RUDN Journal of Law |
Subjects: | |
Online Access: | http://journals.rudn.ru/law/article/viewFile/26036/19205 |
id |
doaj-14d6ced1a85046c88f5fa0fc9865a076 |
---|---|
record_format |
Article |
spelling |
doaj-14d6ced1a85046c88f5fa0fc9865a0762021-03-26T15:00:26ZengPeoples’ Friendship University of Russia (RUDN University)RUDN Journal of Law2313-23372408-90012021-12-01251678610.22363/2313-2337-2021-25-1-67-8619898Legal regulation of gene editing procedure: USA and EU experienceElena N. Trikoz0Diana M. Mustafina-Bredikhina1Elena E. Gulyaeva2MGIMO University; Peoples' Friendship University of Russia (RUDN University)Peoples' Friendship University of Russia (RUDN University)Diplomatic Academy of the Ministry of Foreign Affairs of the Russian FederationThe problem of legal regulation of gene editing in recent years has obviously become global in nature due to the lack of unified systematic legislation in the world. The authors set a goal to study the main existing regulatory legal acts and determine whether there is currently an array of legislation that protects and at the same time establishes responsibility for the editors of the genome and persons who have given consent to it, before future generations, who will receive the edited gene, but who did not actually ask for it. The authors analyzed the most known general public cases related to patent disputes for the CRISPR-Cas9 genome editing technology and came to the conclusion that the strong desire to obtain the legal status of the author of the CRISPR/Cas9 genome modification technology is explained not by scientific ambitions but by commercial interest in a promising technology.http://journals.rudn.ru/law/article/viewFile/26036/19205human rightsinternational biolawlegal and ethical fieldsgenomegene editingbiomedical techniquespatent lawcrispr-cas9 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elena N. Trikoz Diana M. Mustafina-Bredikhina Elena E. Gulyaeva |
spellingShingle |
Elena N. Trikoz Diana M. Mustafina-Bredikhina Elena E. Gulyaeva Legal regulation of gene editing procedure: USA and EU experience RUDN Journal of Law human rights international biolaw legal and ethical fields genome gene editing biomedical techniques patent law crispr-cas9 |
author_facet |
Elena N. Trikoz Diana M. Mustafina-Bredikhina Elena E. Gulyaeva |
author_sort |
Elena N. Trikoz |
title |
Legal regulation of gene editing procedure: USA and EU experience |
title_short |
Legal regulation of gene editing procedure: USA and EU experience |
title_full |
Legal regulation of gene editing procedure: USA and EU experience |
title_fullStr |
Legal regulation of gene editing procedure: USA and EU experience |
title_full_unstemmed |
Legal regulation of gene editing procedure: USA and EU experience |
title_sort |
legal regulation of gene editing procedure: usa and eu experience |
publisher |
Peoples’ Friendship University of Russia (RUDN University) |
series |
RUDN Journal of Law |
issn |
2313-2337 2408-9001 |
publishDate |
2021-12-01 |
description |
The problem of legal regulation of gene editing in recent years has obviously become global in nature due to the lack of unified systematic legislation in the world. The authors set a goal to study the main existing regulatory legal acts and determine whether there is currently an array of legislation that protects and at the same time establishes responsibility for the editors of the genome and persons who have given consent to it, before future generations, who will receive the edited gene, but who did not actually ask for it. The authors analyzed the most known general public cases related to patent disputes for the CRISPR-Cas9 genome editing technology and came to the conclusion that the strong desire to obtain the legal status of the author of the CRISPR/Cas9 genome modification technology is explained not by scientific ambitions but by commercial interest in a promising technology. |
topic |
human rights international biolaw legal and ethical fields genome gene editing biomedical techniques patent law crispr-cas9 |
url |
http://journals.rudn.ru/law/article/viewFile/26036/19205 |
work_keys_str_mv |
AT elenantrikoz legalregulationofgeneeditingprocedureusaandeuexperience AT dianammustafinabredikhina legalregulationofgeneeditingprocedureusaandeuexperience AT elenaegulyaeva legalregulationofgeneeditingprocedureusaandeuexperience |
_version_ |
1724201995574706176 |